NR4A1 and breast cancer: Currently, multiple ongoing trials are testing the efficacy of RC48 in HER2-low advanced breast cancer (NCT05831878, CT04400695), hormone receptor-positive (HR+) MBC (CT05904964), or in combination with penpulimab as neoadjuvant therapy in HER2+ BC (NCT05726175).